Drug intelligence / Profile preview

Lacriact

Development stage: Preclinical
Modality: Device-based Delivery → Drug Delivery Systems
Administration: Ophthalmic

Overview

Lacriact is a preservative-free ophthalmic medical-device eye drop formulated to relieve symptoms of dry eye disease by providing lubrication and protection to the ocular surface through localized physical action rather than pharmacological or immunological mechanisms.[15] It is being evaluated in an open, non-comparative clinical trial for performance and tolerability in patients with dry eye, where its primary role is to stabilize the tear film, reduce discomfort, and improve ocular surface integrity.[13][15]

Brand names: Lacriact

Beyond the preview

Go deeper on Lacriact.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lacriact.

Explore the full profile